Business Context and Reporting Period
Company: Invivyd, Inc. (IVVD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Invivyd is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for viral infectious diseases. Its primary commercial product is PEMGARDA (pemivibart), which received Emergency Use Authorization (EUA) in March 2024 for the pre-exposure prophylaxis of COVID-19 in immunocompromised patients. The company is advancing VYD2311, a next-generation mAb candidate for COVID-19, and has selected VBY329 for RSV prevention.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Product Revenue (Net) | $53.4 million | $25.4 million |
| Cost of Product Revenue | $3.7 million | $1.6 million |
| Gross Profit | $49.7 million | $23.8 million |
| Research & Development (R&D) Expenses | $38.3 million | $137.3 million |
| Selling, General & Administrative (SG&A) | $66.9 million | $63.4 million |
| Net Loss | $(52.5) million | $(169.9) million |
| Cash and Cash Equivalents (End of Period) | $226.7 million | $69.3 million |
| Accumulated Deficit | $(954.5) million | $(902.0) million |
Note: The filing text does not provide a specific "Operating Margin" or "Net Margin" percentage, but the Net Loss decreased significantly year-over-year.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased by $28.0 million (110% increase) driven by expanded sales of PEMGARDA following its 2024 launch.
- Expense Reduction: Total operating expenses decreased by $93.3 million. R&D expenses dropped $99.0 million, primarily due to reduced contract costs for the PEMGARDA Phase 3 trial and commercial manufacturing, as well as lower costs for the VYD2311 program.
- Improved Loss Position: Net loss narrowed by $117.4 million compared to 2024, reflecting revenue growth and significant cost containment.
- Liquidity Improvement: Cash and cash equivalents increased by $157.3 million, bolstered by $215.6 million in net cash provided by financing activities (including underwritten public offerings and ATM sales).
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Based on current operating plans and excluding future revenues or external financing, cash reserves are insufficient to fund operations beyond one year from the issuance of the financial statements.
Outlook and Pipeline
- PEMGARDA: Commercialization continues in the U.S. for immunocompromised patients. The EUA remains contingent on the frequency of resistant SARS-CoV-2 variants remaining below 90%.
- VYD2311: Initiated the Phase 3 DECLARATION trial in December 2025 (top-line data expected mid-2026). Received FDA Fast Track designation. The LIBERTY trial (comparing VYD2311 to mRNA vaccines) was aligned with the FDA in February 2026.
- VBY329: Selected as an RSV candidate in November 2025; IND readiness expected in H2 2026.
Key Risks
- Regulatory Risk: PEMGARDA is authorized only under EUA. If the EUA is revoked or the public health emergency declaration ends, the company must pursue traditional BLA approval to continue sales.
- Viral Evolution: Emerging SARS-CoV-2 variants could reduce the efficacy of PEMGARDA or VYD2311, potentially leading to EUA revocation or trial failure.
- Manufacturing Concentration: The company relies exclusively on WuXi Biologics (China-based) for manufacturing. Geopolitical tensions or U.S. legislation (e.g., BIOSECURE Act) could disrupt supply chains.
- Financing Needs: The company requires additional funding via equity, debt, or collaborations to sustain operations and development.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion and the status of any new financing efforts post-filing.
- PEMGARDA Sales Trends: Monitor quarterly revenue reports to assess if sales growth is sustainable given the limited addressable market (immunocompromised patients).
- VYD2311 Trial Enrollment: Track the progress of the DECLARATION Phase 3 trial and any FDA feedback regarding the trial design.
- Manufacturing Risks: Review updates on the BIOSECURE Act and any potential restrictions on WuXi Biologics that could impact supply.
- EUA Status: Monitor FDA announcements regarding the status of the COVID-19 public health emergency declaration and variant susceptibility thresholds.